AgomAb Therapeutics NV Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Equivalents	221.59	86.42	171.46
Short-Term Investments	30.39	30.1	-
Cash & Short-Term Investments	251.98	116.51	171.46
Cash Growth	46.96%	-32.05%	-
Other Current Assets	6.5	4.72	2.39
Total Current Assets	258.48	121.24	173.85
Net Property, Plant & Equipment	1.41	1.59	1.99
Other Intangible Assets	20.11	20.11	20.11
Goodwill	8.61	8.61	8.61
Long-Term Investments	0.01	0.01	0.01
Other Long-Term Assets	2.3	2.15	1.79
Total Assets	290.92	153.71	206.36
Accounts Payable	11.84	10.27	8.05
Accrued Expenses	1.26	1.55	0.8
Current Portion of Leases	0.23	0.25	0.27
Other Current Liabilities	6.74	6.53	-
Total Current Liabilities	20.07	18.59	9.13
Long-Term Leases	0.91	1.01	1.27
Other Long-Term Liabilities	4.57	3.21	7.88
Total Long-Term Liabilities	5.48	4.22	9.15
Total Liabilities	25.55	22.8	18.28
Common Stock	304.62	223.07	223.07
Additional Paid-in Capital	187.73	90.51	85.16
Accumulated Other Comprehensive Income	-14.36	-0.97	-0.97
Retained Earnings	-212.62	-181.71	-119.18
Shareholders' Equity	265.38	130.9	188.08
Total Liabilities & Equity	290.92	153.71	206.36
Total Debt	1.14	1.25	1.55
Net Cash (Debt)	250.84	115.26	169.91
Net Cash Growth	47.63%	-32.17%	-
Net Cash Per Share	12.15	213.00	314.00
Book Value	265.38	130.9	188.08
Book Value Per Share	12.85	241.91	347.57
Tangible Book Value	236.65	102.18	159.36
Tangible Book Value Per Share	11.46	188.83	294.50

SEC Filings: 10-K · 10-Q